JIANGSU HENGRUI MEDICINE CO., LTD.;SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
发明人:
YE, XIN,叶鑫,葉鑫,SUN, LE,孙乐,孫樂,XU, SHAOYU,徐韶瑜,HU, QIYUE,胡齐悦,胡齊悅,TAO, WEIKANG,陶维康,陶維康,ZHANG, LIANSHAN,张连山,張連山
申请号：
TW106141160
公开号：
TW201819413A
申请日:
2017.11.27
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
The present invention relates to a CD47 antibody, antigen-binding fragments, and pharmaceutical use thereof. Furthermore, the present invention relates to chimeric and humanized antibodies comprising the CDR regions of the present CD47 antibody, as well as pharmaceutical compositions comprising the present CD47 antibody and antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized CD47 antibody, and its use in preparation of a medicament for the treatment of CD47 pathway related disease.本發明涉及CD47抗體、其抗原結合片段及其醫藥用途。進一步地，本發明涉及包含所述CD47抗體CDR區的嵌合抗體、人源化抗體，以及包含人CD47抗體及其抗原結合片段的醫藥組成物，以及其作為抗癌藥物的用途。尤其地，本發明涉及人源化的CD47抗體在製備用於治療CD47通路相關疾病的藥物中的用途。
